A Zebrafish Model of Myelodysplastic Syndrome Produced through tet2 Genomic Editing

Molecular and Cellular Biology

Volumn 35, Issue 5, 2015, Pages 789-804

  Gjini, Evisa ^a   Mansour, Marc R ^a,g   Sander, Jeffry D ^b,c   Moritz, Nadine ^a   Nguyen, Ashley T ^a   Kesarsing, Michiel ^a   Gans, Emma ^a   He, Shuning ^a   Chen, Si ^a   Ko, Myunggon ^d   Kuang, You Yi ^e   Yang, Song ^f   Zhou, Yi ^f   Rodig, Scott ^h   Zon, Leonard I ^f   Joung, J Keith ^b,c   Rao, Anjana ^d   Look, A Thomas ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^e SOUTH CHINA SEA FISHERIES RESEARCH INSTITUTE   (China)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; BETA ACTIN; MESSENGER RNA; OXIDOREDUCTASE; TEN ELEVEN TRANSLOCATION 1 PROTEIN; TEN ELEVEN TRANSLOCATION 2 PROTEIN; TEN ELEVEN TRANSLOCATION 3 PROTEIN; UNCLASSIFIED DRUG; ZINC FINGER NUCLEASE; DIOXYGENASE; DNA BINDING PROTEIN; TET2 PROTEIN, ZEBRAFISH; ZEBRAFISH PROTEIN;

ANIMAL TISSUE; ARTICLE; EMBRYO; ENZYME ACTIVE SITE; ERYTHROCYTE; GENETIC MANIPULATION; HEMATOPOIESIS; HEMATOPOIETIC CELL; INDEL MUTATION; KIDNEY MEDULLA; LOSS OF FUNCTION MUTATION; LYMPHOCYTE; MYELODYSPLASTIC SYNDROME; MYELOID PROGENITOR CELL; NONHUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; ZEBRA FISH; ANIMAL; CELL DIFFERENTIATION; CPG ISLAND; CYTOLOGY; DISEASE MODEL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; HEMATOPOIETIC STEM CELL; HUMAN; IN SITU HYBRIDIZATION; KIDNEY; METABOLISM; MUTATION; PHYSIOLOGY; STEM CELL;

DANIO RERIO;

ANIMALS; CATALYTIC DOMAIN; CELL DIFFERENTIATION; CPG ISLANDS; DIOXYGENASES; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENOTYPE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; IN SITU HYBRIDIZATION; KIDNEY; MUTATION; MYELODYSPLASTIC SYNDROMES; STEM CELLS; ZEBRAFISH; ZEBRAFISH PROTEINS;

EID: 84961291997     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00971-14     Document Type: Article

References (51)

1. He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q, Ding J, Jia Y, Chen Z, Li L, Sun Y, Li X, Dai Q, Song CX, Zhang K, He C, Xu GL. 2011. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333:1303-1307. http://dx.doi.org/10.1126 /science.1210944.
2. Pastor WA, Aravind L, Rao A. 2013. TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat Rev Mol Cell Biol 14:341-356. http://dx.doi.org/10.1038/nrm3589.
3. Wu H, Zhang Y. 2014. Reversing DNA methylation: mechanisms, genomics, and biological functions. Cell 156:45-68. http://dx.doi.org/10 .1016/j.cell.2013.12.019.
4. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, Ebert BL. 2011. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364:2496-2506. http://dx.doi.org/10.1056/NEJMoa1013343.
5. Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Patnaik MM, Hanson CA, Pardanani A, Gilliland DG, Levine RL. 2009. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 23:1343-1345. http://dx.doi.org/10.1038/leu.2009.59.
6. Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard F, Viguié F, Quesnel B, Beyne-Rauzy O, Solary E, Vey N, Hunault-Berger M, Fenaux P, Mansat-De Mas V, Delabesse E, Guardiola P, Lacombe C, Vainchenker W, Preudhomme C, Dreyfus F, Bernard OA, Birnbaum D, Fontenay M. 2009. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 114:3285-3291. http://dx.doi.org/10.1182/blood-2009-04-215814.
7. Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, Preudhomme C, Adès L, Fenaux P, Fontenay M. 2011. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 25:1147-1152. http://dx.doi.org/10.1038/leu.2011.71.
8. Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Gangat N, Finke CM, Schwager S, Mullally A, Li CY, Hanson CA, Mesa R, Bernard O, Delhommeau F, Vainchenker W, Gilliland DG, Levine RL. 2009. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 23:905-911. http://dx.doi.org/10.1038/leu.2009.47.
9. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, Finke C, Score J, Gangat N, Mannarelli C, Ketterling RP, Rotunno G, Knudson RA, Susini MC, Laborde RR, Spolverini A, Pancrazzi A, Pieri L, Manfredini R, Tagliafico E, Zini R, Jones A, Zoi K, Reiter A, Duncombe A, Pietra D, Rumi E, Cervantes F, Barosi G, Cazzola M, Cross NC, Tefferi A. 2013. Mutations and prognosis in primary myelofibrosis. Leukemia 27:1861-1869. http://dx.doi.org/10 .1038/leu.2013.119.
10. Nibourel O, Kosmider O, Cheok M, Boissel N, Renneville A, Philippe N, Dombret H, Dreyfus F, Quesnel B, Geffroy S, Quentin S, Roche-Lestienne C, Cayuela JM, Roumier C, Fenaux P, Vainchenker W, Bernard OA, Soulier J, Fontenay M, Preudhomme C. 2010. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood 116:1132-1135. http://dx.doi .org/10.1182/blood-2009-07-234484.
11. Weissmann S, Alpermann T, Grossmann V, Kowarsch A, Nadarajah N, Eder C, Dicker F, Fasan A, Haferlach C, Haferlach T, Kern W, Schnittger S, Kohlmann A. 2012. Landscape of TET2 mutations in acute myeloid leukemia. Leukemia 26:934-942. http://dx.doi.org/10.1038/leu .2011.326.
12. Konstandin N, Bultmann S, Szwagierczak A, Dufour A, Ksienzyk B, Schneider F, Herold T, Mulaw M, Kakadia PM, Schneider S, Spiekermann K, Leonhardt H, Bohlander SK. 2011. Genomic 5-hydroxymethylcytosine levels correlate with TET2 mutations and a distinct global gene expression pattern in secondary acute myeloid leukemia. Leukemia 25: 1649-1652. http://dx.doi.org/10.1038/leu.2011.134.
13. Kosmider O, Delabesse E, de Mas VM, Cornillet-Lefebvre P, Blanchet O, Delmer A, Recher C, Raynaud S, Bouscary D, Viguié F, Lacombe C, Bernard OA, Ifrah N, Dreyfus F, Fontenay M. 2011. TET2 mutations in secondary acute myeloid leukemias: a French retrospective study. Haematologica 96:1059 -1063. http://dx.doi.org/10 .3324/haematol.2011.040840.
14. Chou WC, Chou SC, Liu CY, Chen CY, Hou HA, Kuo YY, Lee MC, Ko BS, Tang JL, Yao M, Tsay W, Wu SJ, Huang SY, Hsu SC, Chen YC, Chang YC, Kuo YY, Kuo KT, Lee FY, Liu MC, Liu CW, Tseng MH, Huang CF, Tien HF. 2011. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood 118:3803-3810. http://dx.doi.org/10.1182/blood-2011-02 -339747.
15. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R, Liu XS, Aravind L, Agarwal S, Maciejewski JP, Rao A. 2010. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468:839-843. http://dx.doi.org/10.1038/nature09586.
16. Busque L, Patel JP, Figueroa ME, Vasanthakumar A, Provost S, Hamilou Z, Mollica L, Li J, Viale A, Heguy A, Hassimi M, Socci N, Bhatt PK, Gonen M, Mason CE, Melnick A, Godley LA, Brennan CW, Abdel-Wahab O, Levine RL. 2012. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 44:1179-1181. http://dx.doi.org/10.1038/ng.2413.
17. Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, Figueroa ME, Vasanthakumar A, Patel J, Zhao X, Perna F, Pandey S, Madzo J, Song C, Dai Q, He C, Ibrahim S, Beran M, Zavadil J, Nimer SD, Melnick A, Godley LA, Aifantis I, Levine RL. 2011. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20:11-24. http://dx.doi.org/10.1016/j.ccr .2011.06.001.
18. Ko M, Bandukwala HS, An J, Lamperti ED, Thompson EC, Hastie R, Tsangaratou A, Rajewsky K, Koralov SB, Rao A. 2011. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci U S A 108: 14566-14571. http://dx.doi.org/10.1073/pnas.1112317108.
19. Li Z, Cai X, Cai CL, Wang J, Zhang W, Petersen BE, Yang FC, Xu M. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 118:4509-4518. http://dx.doi.org/10.1182/blood-2010-12-325241.
20. Quivoron C, Couronné L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O, Do Cruzeiro M, Delhommeau F, Arnulf B, Stern MH, Godley L, Opolon P, Tilly H, Solary E, Duffourd Y, Dessen P, Merle-Beral H, Nguyen-Khac F, Fontenay M, Vainchenker W, Bastard C, Mercher T, Bernard OA. 2011. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20:25-38. http://dx.doi.org/10.1016/j.ccr.2011.06 .003.
21. North TE, Goessling W, Walkley CR, Lengerke C, Kopani KR, Lord AM, Weber GJ, Bowman TV, Jang IH, Grosser T, Fitzgerald GA, Daley GQ, Orkin SH, Zon LI. 2007. Prostaglandin E2 regulates vertebrate hematopoietic stem cell homeostasis. Nature 447:1007-1011. http://dx .doi.org/10.1038/nature05883.
22. Goessling W, Allen RS, Guan X, Jin P, Uchida N, Dovey M, Harris JM, Metzger ME, Bonifacino AC, Stroncek D, Stegner J, Armant M, Schlaeger T, Tisdale JF, Zon LI, Donahue RE, North TE. 2011. Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models. Cell Stem Cell 8:445-458. http://dx.doi.org/10.1016/j.stem.2011.02.003.
23. Cutler C, Multani P, Robbins D, Kim HT, Le T, Hoggatt J, Pelus LM, Desponts C, Chen YB, Rezner B, Armand P, Koreth J, Glotzbecker B, Ho VT, Alyea E, Isom M, Kao G, Armant M, Silberstein L, Hu P, Soiffer RJ, Scadden DT, Ritz J, Goessling W, North TE, Mendlein J, Ballen K, Zon LI, Antin JH, Shoemaker DD. 2013. Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood 122: 3074-3081. http://dx.doi.org/10.1182/blood-2013-05-503177.
24. Bolli N, Payne EM, Rhodes J, Gjini E, Johnston AB, Guo F, Lee JS, Stewart RA, Kanki JP, Chen AT, Zhou Y, Zon LI, Look AT. 2011. cpsf1 is required for definitive HSC survival in zebrafish. Blood 117:3996-4007. http://dx.doi.org/10.1182/blood-2010-08-304030.
25. Payne EM, Bolli N, Rhodes J, Abdel-Wahab OI, Levine R, Hedvat CV, Stone R, Khanna-Gupta A, Sun H, Kanki JP, Gazda HT, Beggs AH, Cotter FE, Look AT. 2011. Ddx18 is essential for cell-cycle progression in zebrafish hematopoietic cells and is mutated in human AML. Blood 118: 903-915. http://dx.doi.org/10.1182/blood-2010-11-318022.
26. Chen W, Dailey HA, Paw BH. 2010. Ferrochelatase forms an oligomeric complex with mitoferrin-1 and Abcb10 for erythroid heme biosynthesis. Blood 116:628-630. http://dx.doi.org/10.1182/blood-2009-12-259614.
27. Shah DI, Takahashi-Makise N, Cooney JD, Li L, Schultz IJ, Pierce EL, Narla A, Seguin A, Hattangadi SM, Medlock AE, Langer NB, Dailey TA, Hurst SN, Faccenda D, Wiwczar JM, Heggers SK, Vogin G, Chen W, Chen C, Campagna DR, Brugnara C, Zhou Y, Ebert EL, Danial NN, Fleming MD, Ward DM, Campanella M, Dailey HA, Kaplan J, Paw BH. 2012. Mitochondrial Atpif1 regulates heme synthesis in developing erythroblasts. Nature 491:608-612. http://dx.doi.org/10.1038/nature11536.
28. Sood R, English MA, Belele CL, Jin H, Bishop K, Haskins R, McKinney MC, Chahal J, Weinstein BM, Wen Z, Liu PP. 2010. Development of multilineage adult hematopoiesis in the zebrafish with a runx1 truncation mutation. Blood 115:2806-2809. http://dx.doi.org/10.1182/blood-2009 -08-236729.
29. Pase L, Layton JE, Kloosterman WP, Carradice D, Waterhouse PM, Lieschke GJ. 2009. miR-451 regulates zebrafish erythroid maturation in vivo via its target gata2. Blood 113:1794-1804. http://dx.doi.org/10.1182 /blood-2008-05-155812.
30. Keightley MC, Layton JE, Hayman JW, Heath JK, Lieschke GJ. 2011. Mediator subunit 12 is required for neutrophil development in zebrafish. PLoS One 6:e23845. http://dx.doi.org/10.1371/journal.pone.0023845.
31. Bolli N, Payne EM, Grabher C, Lee JS, Johnston AB, Falini B, Kanki JP, Look AT. 2010. Expression of the cytoplasmic NPM1 mutant (NPMc+) causes the expansion of hematopoietic cells in zebrafish. Blood 115:3329-3340. http://dx.doi.org/10.1182/blood-2009-02-207225.
32. North TE, Goessling W, Peeters M, Li P, Ceol C, Lord AM, Weber GJ, Harris J, Cutting CC, Huang P, Dzierzak E, Zon LI. 2009. Hematopoietic stem cell development is dependent on blood flow. Cell 137:736-748. http://dx.doi.org/10.1016/j.cell.2009.04.023.
33. Murayama E, Kissa K, Zapata A, Mordelet E, Briolat V, Lin HF, Handin RI, Herbomel P. 2006. Tracing hematopoietic precursor migration to successive hematopoietic organs during zebrafish development. Immunity 25:963-975. http://dx.doi.org/10.1016/j.immuni.2006.10.015.
34. Westerfield M. 2000. The zebrafish book: a guide for the laboratory use of zebrafish (Danio rerio), 4th ed. University of Oregon Press, Eugene, OR.
35. Sander JD, Yeh JR, Peterson RT, Joung JK. 2011. Engineering zinc finger nucleases for targeted mutagenesis of zebrafish. Methods Cell Biol 104:51-58. http://dx.doi.org/10.1016/B978-0-12-374814-0.00003-3.
36. Sander JD, Dahlborg EJ, Goodwin MJ, Cade L, Zhang F, Cifuentes D, Curtin SJ, Blackburn JS, Thibodeau-Beganny S, Qi Y, Pierick CJ, Hoffman E, Maeder ML, Khayter C, Reyon D, Dobbs D, Langenau DM, Stupar RM, Giraldez AJ, Voytas DF, Peterson RT, Yeh JR, Joung JK. 2011. Selection-free zinc-finger-nuclease engineering by contextdependent assembly (CoDA). Nat Methods 8:67-69. http://dx.doi.org/10.1038/nmeth.1542.
37. Almeida RD, Loose M, Sottile V, Matsa E, Denning C, Young L, Johnson AD, Gering M, Ruzov A. 2012. 5-Hydroxymethyl-cytosine enrichment of non-committed cells is not a universal feature of vertebrate development. Epigenetics 7:383-389. http://dx.doi.org/10.4161/epi.19375.
38. Traver D, Paw BH, Poss KD, Penberthy WT, Lin S, Zon LI. 2003. Transplantation and in vivo imaging of multilineage engraftment in zebrafish bloodless mutants. Nat Immunol 4:1238-1246. http://dx.doi.org /10.1038/ni1007.
39. Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Stevens-Linders E, van Hoogen P, van Kessel AG, Raymakers RA, Kamping EJ, Verhoef GE, Verburgh E, Hagemeijer A, Vandenberghe P, de Witte T, van der Reijden BA, Jansen JH. 2009. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 41:838-842. http://dx.doi.org/10.1038/ng.391.
40. Ge L, Zhang RP, Wan F, Guo DY, Wang P, Xiang LX, Shao JZ. 2014. TET2 plays an essential role in erythropoiesis by regulating lineagespecific genes via DNA oxidative demethylation in a zebrafish model. Mol Cell Biol 34:989-1002. http://dx.doi.org/10.1128/MCB.01061-13.
41. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL. 2009. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114:144-147. http: //dx.doi.org/10.1182/blood-2009-03-210039.
42. Huang Y, Chavez L, Chang X, Wang X, Pastor WA, Kang J, Zepeda-Martínez JA, Pape UJ, Jacobsen SE, Peters B, Rao A. 2014. Distinct roles of the methylcytosine oxidases Tet1 and Tet2 in mouse embryonic stem cells. Proc Natl Acad Sci U S A 111:1361-1366. http://dx.doi.org/10.1073 /pnas.1322921111.
43. Hon GC, Song CX, Du T, Jin F, Selvaraj S, Lee AY, Yen CA, Ye Z, Mao SQ, Wang BA, Kuan S, Edsall LE, Zhao BS, Xu GL, He C, Ren B. 2014. 5mC oxidation by Tet2 modulates enhancer activity and timing of transcriptome reprogramming during differentiation. Mol Cell 56:286-297. http://dx.doi.org/10.1016/j.molcel.2014.08.026.
44. Itzykson R, Kosmider O, Renneville A, Morabito M, Preudhomme C, Berthon C, Adès L, Fenaux P, Platzbecker U, Gagey O, Rameau P, Meurice G, Oréar C, Delhommeau F, Bernard OA, Fontenay M, Vainchenker W, Droin N, Solary E. 2013. Clonal architecture of chronic myelomonocytic leukemias. Blood 121:2186-2198. http://dx.doi.org/10 .1182/blood-2012-06-440347.
45. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Löwenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A. 2010. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553-567. http://dx.doi.org/10 .1016/j.ccr.2010.11.015.
46. Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C, Cowley GS, Root DE, Ebert BL, Kaelin WG, Jr. 2013. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339:1621-1625. http://dx.doi.org/10.1126/science .1231677.
47. Kunimoto H, Fukuchi Y, Sakurai M, Sadahira K, Ikeda Y, Okamoto S, Nakajima H. 2012. Tet2 disruption leads to enhanced self-renewal and altered differentiation of fetal liver hematopoietic stem cells. Sci Rep 2:273. http://dx.doi.org/10.1038/srep00273.
48. Robu ME, Larson JD, Nasevicius A, Beiraghi S, Brenner C, Farber SA, Ekker SC. 2007. p53 activation by knockdown technologies. PLoS Genet 3:e78. http://dx.doi.org/10.1371/journal.pgen.0030078.
49. Robu ME, Zhang Y, Rhodes J. 2012. Rereplication in emi1-deficient zebrafish embryos occurs through a Cdh1-mediated pathway. PLoS One 7:e47658. http://dx.doi.org/10.1371/journal.pone.0047658.
50. Schulte-Merker S, Stainier DY. 2014. Out with the old, in with the new: reassessing morpholino knockdowns in light of genome editing technology. Development 141:3103-3104. http://dx.doi.org/10.1242/dev.112003.
51. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, Kennedy JA, Schimmer AD, Schuh AC, Yee KW, McLeod JL, Doedens M, Medeiros JJ, Marke R, Kim HJ, Lee K, McPherson JD, Hudson TJ, Pan-Leukemia Gene Panel Consortium HALT, Brown AM, Yousif F, Trinh QM, Stein LD, Minden MD, Wang JC, Dick JE. 2014. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506:328-333. http://dx.doi.org/10.1038/nature13038.